Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy
Go back to Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy| (NYSE: BHVN) | Delayed: 14.72 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.72 | 52 Week High | $ | |||
| Open | $14.72 | 52 Week Low | $ | |||
| Day High | $14.72 | P/E | N/A | |||
| Day Low | $14.72 | EPS | $ | |||
| Volume | 5,280 | |||||
